S&CO Inc. Makes New Investment in Illumina, Inc. $ILMN

S&CO Inc. acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 18,000 shares of the life sciences company’s stock, valued at approximately $3,164,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Elyxium Wealth LLC bought a new stake in Illumina in the fourth quarter worth $25,000. TD Waterhouse Canada Inc. purchased a new stake in Illumina during the fourth quarter valued at $26,000. Laurel Wealth Advisors LLC bought a new position in Illumina during the fourth quarter valued at $26,000. Activest Wealth Management lifted its position in Illumina by 671.9% during the fourth quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 215 shares during the last quarter. Finally, Quarry LP purchased a new position in shares of Illumina in the 3rd quarter worth $32,000. 89.42% of the stock is currently owned by institutional investors.

Insider Activity

In other Illumina news, insider Scott M. Davies sold 615 shares of the business’s stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $200.00, for a total transaction of $123,000.00. Following the completion of the transaction, the insider owned 20,338 shares in the company, valued at $4,067,600. The trade was a 2.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 457,858 shares of the business’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total value of $91,617,385.80. Following the transaction, the director owned 2,372,694 shares of the company’s stock, valued at $474,776,069.40. This trade represents a 16.18% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 1,415,351 shares of company stock valued at $255,966,311. 2.90% of the stock is currently owned by company insiders.

Illumina Trading Down 0.9%

ILMN stock opened at $190.89 on Friday. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a twelve month low of $88.00 and a twelve month high of $207.00. The stock has a market capitalization of $28.82 billion, a price-to-earnings ratio of 35.61, a price-to-earnings-growth ratio of 2.69 and a beta of 1.45. The firm’s fifty day simple moving average is $183.78 and its two-hundred day simple moving average is $150.56.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.08. The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft downgraded shares of Illumina to a “hold” rating in a report on Wednesday, August 5th. Wall Street Zen upgraded Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Sanford C. Bernstein reiterated a “market perform” rating and issued a $215.00 price target on shares of Illumina in a research report on Friday, July 31st. Citigroup boosted their price objective on Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a research note on Monday, August 3rd. Finally, Daiwa Securities Group upgraded Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective on the stock in a research report on Thursday, May 14th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $188.40.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.